Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis – a multicenter trial

Table 1 Sensitivity and Specificity of Antibody Assays¹

Infection	Bm14 ELISA Positive/Tested (%)	SXP Cassette Positive/Tested (%)	BmR1 ELISA Positive/Tested (%)	BmR1 Dipstick Positive/Tested (%)
W. bancrofti (n = 35)²	32/35 (91%)	30/33 (2 NC) (91%)	14/31 (4 NC) (45%)	17/30 (5NC) (56.7%)
B. malayi (n = 28)³	27/28 (96%)	7/18 (10 NC) (39%)	28/28 (100%)	27/27 (1NC) (100%)
O. volvulus (n = 20)⁴	11/16 (4 NC) (69%)	9/15 (5 NC) (60%)	0/20 (0%)	1/20 (5%)
Loa (n = 10)⁵	7/9 (1 NC) (78%)	3/7 (3 NC) (43%)	0/10 (0%)	0/9 (1 NC) (0%)
Other (incl. Strongyloides, Echinococcus; n = 20)⁶	0/19 (1 NC) (0%)	0/19 (1 NC) (0%)	0/20 (0%)	0/20 (0%)

¹Specimens were collected from persons with documented infections with the listed parasites; for patients with filarial infections, microfilariae were detected. Abbreviations: NC, no consensus; specimens with a no consensus result were not included in the denominators for calculations.
²Geographic source of specimens provided in Table 2.
³Geographic source of specimens provided in Table 2.
⁴Ten specimens were from Guatemala and 10 were from Ecuador.
⁵Specimens were collected from patients in Benin.
⁶Echinococcus specimens were collected in Kenya; Strongyloides specimens were from several settings where lymphatic filariasis was not endemic.